On the one hand, Shanghai has become the city with the largest number of foreign R&D centers in China. On the other hand, it is reported that Shanghai Pharmaceuticals set up a R&D center in San Diego, the United States.
This R&D center will be dedicated to the development of biopharmaceutical external cooperation and equity investment, helping Shanghai Pharmaceuticals to integrate with the world’s leading biomedical technologies and enhance its overall innovation capabilities in the biomedical field.
Up to now, Shanghai Pharmaceutical has more than 1,000 R&D personnel, 365 invention patents, and 12 innovative drugs and biopharmaceuticals are in the clinical stage.
Shanghai Pharmaceuticals also established the SPH Phililab as a high-end overseas research and development platform, speeding up the transformation and upgrading of Shanghai Pharmaceuticals in drug research and development.
Editor： Zhu Yan